SPY334.57+0.24 0.07%
DIA274.62+0.72 0.26%
IXIC11,010.98-97.09 -0.87%

BMO Capital Maintains Market Perform on Halozyme Therapeutics, Raises Price Target to $17

BMO Capital maintains Halozyme Therapeutics (NASDAQ:HALO) with a Market Perform and raises the price target from $16 to $17.

Benzinga · -

BMO Capital maintains Halozyme Therapeutics (NASDAQ:HALO) with a Market Perform and raises the price target from $16 to $17.